The key objectives of the upcoming meeting include obtaining FDA feedback on the acceptability of BioCardia's proposed submission for approval, based on the safety data observed in the CardiAMP HF Trial. The trial involved 125 ischemic HFrEF patients, and the results indicated a low risk and high potential benefit profile, particularly for patients with elevated biomarkers of heart stress. Notably, the therapy demonstrated a 47% relative risk reduction in all-cause cardiac death and a 37% relative risk reduction in non-fatal major adverse cardiac events, alongside significant improvements in quality of life.
BioCardia's CardiAMP therapy utilizes a patient's own bone marrow cells, delivered via a minimally invasive catheter-based procedure, to enhance capillary density and reduce myocardial tissue fibrosis. This innovative approach is supported by the Maryland Stem Cell Research Fund and is reimbursed by the Centers for Medicare and Medicaid Services (CMS). The company emphasizes that the CardiAMP therapy is currently limited to investigational use under U.S. law.
The submission to the FDA and the planned meeting are seen as critical steps in advancing BioCardia's clinical development efforts and could significantly impact the company's market position and stock performance, given the promising results from the CardiAMP HF trial. Investors and stakeholders will be closely monitoring the developments as BioCardia seeks to navigate the regulatory landscape for its groundbreaking therapy.
